Time-course and dose-effect of omalizumab in treating chronic idiopathic urticaria/chronic spontaneous urticaria-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Time-course and dose-effect of omalizumab in treating chronic idiopathic urticaria/chronic spontaneous urticaria

Published:2024-07-05 Issue:10 Volume:80 Page:1461-1469
ISSN:0031-6970
Container-title:European Journal of Clinical Pharmacology
language:en
Short-container-title:Eur J Clin Pharmacol

Author:

Zhao Aiping,Zhang Ke,Wang Zhen,Ye Kaihe,Xu Zhaosi,Gong Xiao,Zhu Guanghu

Funder

Scientific Research and Technology Development Program of Guangxi Zhuang Autonomous Region

Natural Science Foundation of Guangxi Zhuang Autonomous Region

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s00228-024-03725-2.pdf

Reference27 articles.

1. Zuberbier T, Asero R, Bindslev-Jensen C et al (2009) EAACI/GA(2) LEN/EDF/WAO guideline: management of urticaria. Allergy 64(10):1427–1443

2. Zuberbier T, Aberer W, Asero R et al (2014) The EAACI/GA(2) LEN/EDF/WAO guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy 69(7):868–887

3. Zuberbier T, Aberer W, Asero R et al (2018) The EAACI/GA2LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy 73(7):1393–1414

4. Bergstrom KG (2013) Chronic urticaria: omalizumab and review of therapeutic options. J Drugs Dermatol 12(6):715–716

5. Staubach P, Metz M, Chapman-Rothe N et al (2016) Effect of omalizumab on angioedema in H1-antihistamine-resistant chronic spontaneous urticaria patients: results from X-ACT, a randomized controlled trial. Allergy 71(8):1135–1144

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP